Blueprint Medicines (BPMC) Misses Q3 EPS by 37c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• Docusign Inc. (DOCU) PT Raised to $58 at BofA Securities
• BW LPG Limited (BWLP) Reports Q1 EPS of $0.79